Impaired interleukin-2 production in T-cells from a patient with Wiskott-Aldrich syndrome: Basis of clinical effect of interleukin-2 replacement therapy

European Journal of Pediatrics

Volumn 159, Issue 8, 2000, Pages 633-634

  Azuma, Hiroshi ^a,b   Oshima, Miho ^b   Ito, Kiminari ^b   Okuno, Akimasa ^b   Kawabata, Isao ^b   Banba, Kenzo ^c   Murahashi, Hideaki ^d   Sekine, Teruaki ^e   Kato, Yoichi ^e   Ikebuchi, Kenji ^a   Ikeda, Hisami ^a  

^a JAPANESE RED CROSS SOCIETY   (Japan)

^b ASAHIKAWA MEDICAL COLLEGE   (Japan)

^c HITACHI LTD   (Japan)

^d Nissho Corporation   (Japan)

^e Intl Cancer Centre Laboratory   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

ARTICLE; HUMAN; IMMUNOSTIMULATION; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME; WISKOTT ALDRICH SYNDROME;

EID: 0033925403     PISSN: 03406199     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00008395     Document Type: Article

References (4)

1. 1. Azuma H, Sakata H, Saijo M, Okuno A (1993) Effect of interleukin 2 on intractable herpes virus infection and chronic eczematoid dermatitis in a patient with Wiskott-Aldrich syndrome. Eur J Pediatr 152: 998-1000
2. 2. Gallego MD, Santamaria M, Pena J, Molina IJ (1997) Defective actin reorganization and polymerization of Wiskott-Aldrich T cells in response to CD3-mediated stimulation. Blood 90: 3089-3097
3. 3. Molina IJ, Sancho J, Terhorst C, Rosen FS, Remold O'Donnell E (1993) T cells of patients with the Wiskott-Aldrich syndrome have a restricted defect in proliferative responses. J Immunol 151: 4383-4390
4. 4. Sekine T, Shiraiwa H, Yamazaki T, Tobisu K, Kakizoe T (1993) A feasible method for expansion of peripheral blood lymphocytes by culture with immobilized anti-CD3 monoclonal antibody and interleukin-2 for use in adoptive immunotherapy of cancer patients. Biomed Pharmacother 47: 73-78